Research objective. To determine the relationship between allelic variants of the polymorphic marker of PAI-1 gene with the risk factors of ischemic heart disease (IHD) in Uzbek nationality. Material and methods. 126 respondents were examined: 61 patients with stable angina (SA) aged 45 to 60 years (males) who were hospitalized in the cardiology department of the 1st TMA clinic in Tashkent. In the comparison group were 65 unrelated males of Uzbek nationality without clinical signs of coronary artery disease. The examined noted: arterial hypertension (AH) in 53 people, hypercholesterolemia (HCH) in 38 people, obesity in 23 people, smoking in 22 people. The diagnosis –SA was verificated in compliance with classification of IHD accepted at the IV congress of cardiologists (2000) became criteria of including of patients. Functional class of SA was established on the basis of classification of stable angina of the Canadian society of cardiologists (1976) and exciting test veloergometry. Criteria of an exception of a research- patients with unstable angina, myocardial infarction (MI), an acute and chronic heart, renal, liver failure, patients with an arrhythmia, acute disorders of a cerebral circulation, the diabetes mellitus, malignant neoplasms. Results. The analysis of genotyping of the studied persons of the Uzbek nationality showed that, in patients with IHD mutagen allele 4G of gene PAI-1 in homozygous (4G/4G) and heterozygous (4G/5G) state what makes 21,3% and 47,5%, respectively, meets more than in group of healthy faces at which given distributions of genotypes made 9,2% and 38,5%. Points these data probability of influence of existence of 4G allele of PAI-1 gene, especially in a heterozygous state, to development of IHD. 5G/5G the group of healthy faces in number of 34 people in 52.3% of cases, than at 19 (31,1%) IHD patients caused a stir in the greatest occurrence of a favorable genotype. Thus, these differences have the high statistical importance and wear, nonrandom character (р<0.05). Conclusion. The genotyping of the coagulation factor PAI-1 in the examined patients revealed the presence of unfavorable genotypes 4G/4G and 4G/5G was established more often in patients with coronary artery disease in 21.3% and 47.5% of cases, respectively, compared with the group of healthy individuals who This distribution of genotypes was 9.2% and 38.5%. Whereas, the prevalence rate of the 5G/5G genotype was prevalent in 52.3% of the control group over the spread of 31.1% of patients in the IHD.
1. Hendrix P, Foreman PM, Harrigan MR, Fisher WS, Vyas NA, Lipsky RH, et al. Association of Plasminogen Activator Inhibitor 1 (SERPINE1) Polymorphisms and Aneurysmal Subarachnoid Hemorrhage // World Neurosurg. 2017 Sep;105:672–7. 2. Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo // Kidney Int. 2000;58(1):251–9. 3. Hassani Idrissi H, Hmimech W, Diakite B, Korchi F, Baghdadi D, Habbal R, et al. Association of G894T eNOS, 4G/5G PAI and T1131C APOA5 polymorphisms with susceptibility to myocardial infarction in Morocco // Meta Gene. 2016;9:56–61. 4. Nordt TK, Lohrmann J, Bode C. Regulation of PAI-1 expression by genetic polymorphisms. Impact on atherogenesis // Thromb Res [Internet]. 2001 Sep 30 [cited 2019 Dec 14];103 Suppl 1:S1-5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11567663 5. Ding J, Nicklas BJ, Fallin MD, de Rekeneire N, Kritchevsky SB, Pahor M, et al. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke // Am Heart J [Internet]. 2006 Dec 1 [cited 2019 Dec 14];152(6):1109–15. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0002870306005278?via%3Dihub 6. Jung RG, Simard T, Labinaz A, Ramirez FD, Di Santo P, Motazedian P, et al. Role of plasminogen activator inhibitor-1 in coronary pathophysiology //Thromb Res. 2018 Apr;164:54–62. 7. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease // Circulation. 1989;79(4):733–43. 8. Sasaki A, Kurisu A, Ohno M, Ikeda Y. Overweight/Obesity, Smoking, and Heavy Alcohol Consumption Are Important Determinants of Plasma PAI-1 Levels in Healthy Men // Am J Med Sci. 2001 Jul;322(1):19–23. 9. Figueras J, Monasterio J, Domingo E, Meneses B, Nieto E, Cortadellas J, et al. Prothrombotic profile in patients with vasospastic or non vasospastic angina and non significant coronary stenosis // Thromb J. 2011;9:1–7. 10. Deyoung MB, Tom C, Dichek DA. Formation in Balloon-Injured Rat Carotid Arteries. 2001;1:1972–7. 11. Katrancıoğlu N, Karahan O, Küçükkurtulgan H, Sanrı US, Kılıç AT. PAI-1 4G/4G gene polymorphism is associated with higher serum lipid level in Turkish population. Cumhur Tıp Derg [Internet]. 2011;33(3):307–11. Available from: http://dergipark.ulakbim.gov.tr/cumucmj/article/viewFile/938/1008000989 12. Assawamakin A, Sriratanaviriyakul N, Lalerd Y, Thongnoppakhun W, Praditsap O, Tongsima S, et al. Meta-analysis of the plasminogen activator inhibitor-1 (PAI-1) gene with insertion/deletion 4G/5G polymorphism and its susceptibility to ischemic stroke in Thai population // Asian Biomed. 2012;6(2):203–17. 13. Boekholdt SM, Bijsterveld NR, Moons AHM, Levi M, Büller HR, Peters RJG. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: A systematic review // Circulation. 2001;104(25):3063–8. 14. Balta G, Altay C, Gurgey A. PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs // Am J Hematol. 2002;71(2):89–93. 15. Eriksson P, Kallin B, Van’t Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen- activator inhibitor 1 gene is associated with myocardial infarction // Proc Natl Acad Sci U S A. 1995;92(6):1851–5. 16. Spronk HMH, van der Voort D, ten Cate H. Blood coagulation and the risk of atherothrombosis: A complex relationship // Thromb J. 2004;2:1–10. 17. Sarecka B, Zak I, Krauze J. Synergistic effects of the polymorphisms in the PAI-1 and IL-6 genes with smoking in determining their associated risk with coronary artery disease // Clin Biochem. 2008 May;41(7–8):467–73. 18. Hoekstra T, Geleijnse JM, de Waart F, Nederhand R, Kluft C, Kok FJ, et al. The 4G/5G-polymorphism in the PAI-1 gene is not associated with markers of atherosclerosis in male smokers // Thromb Res. 2002 Aug;107(3–4):115–9. 19. Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, Navis G, et al. Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels // Genomics. 2007 Mar;89(3):362–9. 20. Jeng JR, Harn HJ, Yueh KC, Jeng CY, Shieh SM. Plasminogen activator inhibitor-1 and angiotensin I converting enzyme gene polymorphism in patients with hypertension // Am J Hypertens. 1998;11(2):235–9. 21. Margaglione M, Grandone E, Vecchione G, Cappucci G, Giuliani N, Colaizzo D, et al. Plasminogen Activator Inhibitor-1 (PAI-1) Antigen Plasma Levels in Subjects Attending a Metabolic Ward: Relation to Polymorphisms of PAI-1 and Angiontensin Converting Enzyme (ACE) Genes // Arterioscler Thromb Vasc Biol [Internet]. 1997 Oct [cited 2019 Nov 19];17(10):2082–7. Available from: https://www.ahajournals.org/doi/10.1161/01.ATV.17.10.2082 22. Saidi S, Slamia LB, Mahjoub T, Ammou SB, Almawi WY. Association of PAI-1 4G/5G and -844G/A Gene Polymorphism and Changes in PAI-1/tPA Levels in Stroke: A Case-Control Study // J Stroke Cerebrovasc Dis. 2007 Jul;16(4):153–9. 23. Jastrzȩbska M, Widecka K, Naruszewicz M, Ciechanowicz A, Janczak-Bazan A, Foltyňska A, et al. Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms // Nutr Metab Cardiovasc Dis. 2004 Oct;14(5):259–69. 24. Hassani Idrissi H, Hmimech W, Diakite B, Korchi F, Habbal R, Nadifi S. Synergic predisposing effect of G894T (eNOS), 4G/5G (PAI) and T1131C (APOA5) polymorphisms to myocardial infarction // Gene Reports. 2018 Jun;11:165–9. 25. Panahloo A, Mohamed-Ali V, Gray RP, Humphries SE, Yudkin JS. Plasminogen activator inhibitor-1 (PAI-1) activity post myocardial infarction: the role of acute phase reactants, insulin-like molecules and promoter (4G/5G) polymorphism in the PAI-1 gene // Atherosclerosis. 2003 Jun;168(2):297–304. 26. Jeng J-R. Association of PAI-1 gene promoter 4g/5g polymorphism with plasma PAI-1 activity in Chinese patients with and without hypertension. //Am J Hypertens. 2003 Apr;16(4):290–6. 27. Huan W, Jiuying L, Hui C. GW25-e0783 Association between Plasma PAI-1 Levels and Clock Genes Polymorphisms in Primary Hypertensions // J Am Coll Cardiol. 2014 Oct;64(16):C175. 28. Natesirinilkul R, Sasanakul W, Chuansumrit A, Kadegasem P, Visudtibhan A, Wongwerawattanakoon P, et al. Global Fibrinolytic Activity, PAI-1 Level, and 4G/5G Polymorphism in Thai Children with Arterial Ischemic Stroke // J Stroke Cerebrovasc Dis. 2014 Nov;23(10):2566–72. 29. Abboud N, Ghazouani L, Saidi S, Belhaj Khlifa S, Addad F, Mahjoub M, et al. A016 Association of PAI-1 4G/5G and -844G/A gene polymorphisms and changes in PAI-1/TPA levels in myocardial infarction. A casecontrol study // Arch Cardiovasc Dis. 2009 Mar;102:S12. 30. Boeva O. konstitutsionalnie i geneticheskie faktori v prognozirovanii riska povtornix obostreniy ishemicheskoy bolezni serdsa // Avtoreferat.Stavropol, 2008.- 342 s 31.Zateyshchikov D.A., Selesneva N.D.,Minouchkina L.O., O.Yu.Kudryashova, SereginYu.V., Nosikov V.V.,Barinov V.G., Cimbalova T.E., Sidorenko B.A. Plasminogen inhibitor activator gene 4G(-675)5G polymorphism and hemostasis in patients with ischemic heart disease // Trombi,krovotochivost I bolezni sosudov 2002 32. Kumagai N, Takahashi N, Kinoshita M, Tsunematsu S, Tsuchimoto K, Saito H, et al. Polymorphisms of NS5B protein relates to early clearance of hepatitis C virus by interferon plus ribavirin: a pilot study // J Viral Hepat. 2004;11:225--35. 33. Abdumalikova F.B. Influence of psychological and personality characteristics of patients with coronary artery disease on the phenotype of platelets // european journal of pharmaceutical and medical research 2019;6(5):662–6. 34. Zhang H, Dong P, Yang X, Liu Z. Is Associated With Coronary Artery Disease Risk : a Meta-Analysis Commonly Studied Functional Variant in the // Int J Clin Exp Med 2014;7(10):3777–88. 35. Festa A, D’Agostino R, Rich SS, Jenny NS, Tracy RP, Haffner SM. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, hispanics, and non-hispanic whites: The Insulin Resistance Atherosclerosis Study // Circulation. 2003;107(19):2422–7. 36. Hassani Idrissi H, Hmimech W, Diakite B, Korchi F, Baghdadi D, Habbal R, et al. Association of G894T eNOS, 4G/5G PAI and T1131C APOA5 polymorphisms with susceptibility to myocardial infarction in Morocco // Meta Gene. 2016 Sep;9:56–61. 37. Al-Wakeel H, Sewelam N, Khaled M, Abdelbary A. Impact of PAI-1 4G/5G and C > G polymorphisms in acute ST elevation myocardial infarction and stable angina patients: A single center Egyptian study // Egypt J Med Hum Genet. 2018 Oct;19(4):325–31. 38. Martínez-Quintana E, Chirino R, Nieto-Lago V, Pérez-Jiménez P, López-Ríos L, Rodríguez-González F. Prognostic value of ACE I/D, AT1R A1166C, PAI-I 4G/5G and GPIIIa a1/a2 polymorphisms in myocardial infarction // Cardiol J. 2014;21(3):229–37.
Khasanova, N.А.; Zokirova, M.B.; Nuritdinova, N.B.; and Tseluyko, V.I.
"ASSOCIATIVE RELATIONSHIP OF THE PLASMINOGEN ACTIVATOR INHIBITOR-1 GENE POLYMORPHISM WITH RISK FACTORS OF ISCHEMIC HEART DISEASE,"
Central Asian Journal of Medicine: Vol. 2020
, Article 3.
Available at: https://uzjournals.edu.uz/tma/vol2020/iss2/3